Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04008329
Recruiting Observational

A Registered Cohort Study on Amyotrophic Lateral Sclerosis

NCT04008329 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Observational
Started
2019-07-05
Last updated
2021-03-22

Condition(s) studied

Amyotrophic Lateral Sclerosis

Study summary

Amyotrophic lateral sclerosis (ALS) is a kind of motor neuron degeneration disorder without effective therapy. This registered cohort study will provide further insights into the clinical course of ALS, and investigate disease-relative risk factors and the genetic background of Chinese ALS patients.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Amyotrophic Lateral Sclerosis patients fulfilling the El Escorial criteria (including definite, probable and possible) * Progressive muscular atrophy * Primary lateral sclerosis * Progressive bulbar palsy Exclusion Criteria: * History of serious head trauma or neuropsychiatric disease * Decline to participate

Primary outcome measure(s)

  • Age at death — 10 years
    the time when patient die
  • Age of endotracheal intubation or tracheotomy — 10 years
    the time for the patient accepted endotracheal intubation or tracheotomy

Trial sites (1)

FacilityCityRegionStatus
Department of Neurology, First Affiliated Hospital of Fujian Medical University Fuzhou Fujian Recruiting

More First Affiliated Hospital of Fujian Medical University trials in China

68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study Recruiting
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer Recruiting
Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes Recruiting
68Ga-FAPI PET/CT in Patients With Various Types of Cancer Recruiting
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI Recruiting

Other trials for the same condition

An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS Active, not recruiting
China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine Recruiting
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis Recruiting
Tofacitinib in Patients With Amyotrophic Lateral Sclerosis Starting soon
Research on Wireless Brain Implant System for General Control of External Devices Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04008329 on ClinicalTrials.gov ↗ ← All trials in China